SHILPAMED Shilpa Medicare Ltd Expansion Plans Announcement 2024 - NDA Submission Shilpa Medicare Ltd.s partner, Unicycive, has submitted a New Drug Application (NDA) to the U.S. FDA for a treatment targeting hyperphosphatemia in chronic kidney disease patients, marking Shilpas first regulatory submission from its CDMO projects..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd